Suppr超能文献

拉帕替尼与多西他赛联合给药可增加小鼠小肠内多西他赛的暴露量,但不增加阿霉素的暴露量。

Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice.

机构信息

Department of Clinical Sciences, Animal Cancer Center, Colorado State University, Fort Collins, USA.

出版信息

Anticancer Drugs. 2013 Oct;24(9):958-68. doi: 10.1097/CAD.0b013e3283645e1a.

Abstract

Combination therapy is increasingly being utilized for the treatment of metastatic breast cancer. However, coadministration of drugs, particularly agents that are substrates for or inhibitors of p-glycoprotein, can result in increased tissue toxicity. Unfortunately, determination of levels of chemotherapeutics in human tissues is challenging, and plasma drug concentrations are not always indicative of tissue toxicokinetics or toxicodynamics, especially when tissue penetration is altered. The aim of the present work was to determine whether concomitant administration of compounds currently being combined in clinical trials for metastatic breast cancer treatment alters plasma and tissue pharmacokinetics in mice if both agents are p-glycoprotein substrates and/or inhibitors. Accordingly, we investigated the pharmacokinetic interactions of the classic cytotoxics and p-glycoprotein substrates docetaxel and doxorubicin when administered concurrently with the targeted agent and p-glycoprotein inhibitor lapatinib. Our time-course plasma and tissue distribution studies showed that coadministration of lapatinib with doxorubicin did not appreciably alter the pharmacokinetics of this anthracycline in the plasma or six tissues evaluated in mice, presumably because, at doses relevant to human exposure, lapatinib inhibition of p-glycoprotein did not significantly alter doxorubicin transport out of these tissue compartments. However, combining lapatinib with docetaxel significantly increased intestinal exposure to this chemotherapeutic, which has clinical implications for enhancing gastrointestinal toxicity. The significant lapatinib-docetaxel interaction is likely CYP3A4-mediated, suggesting that caution should be exercised when this combination is administered, particularly to patients with compromised CYP3A activity, and recipients should be monitored closely for enhanced toxicity, particularly for adverse effects on the intestine.

摘要

联合治疗越来越多地被用于治疗转移性乳腺癌。然而,药物的联合使用,特别是那些 P 糖蛋白的底物或抑制剂的药物,可能会导致组织毒性增加。不幸的是,确定人类组织中化疗药物的水平具有挑战性,并且血浆药物浓度并不总是指示组织毒代动力学或毒效动力学,特别是当组织穿透性改变时。本研究的目的是确定如果两种药物都是 P 糖蛋白的底物和/或抑制剂,当前正在临床研究中联合用于转移性乳腺癌治疗的化合物联合给药是否会改变小鼠的血浆和组织药代动力学。因此,我们研究了经典细胞毒素和 P 糖蛋白底物多西紫杉醇和阿霉素与靶向药物和 P 糖蛋白抑制剂拉帕替尼同时给药时的药代动力学相互作用。我们的时间过程血浆和组织分布研究表明,拉帕替尼与阿霉素联合给药不会明显改变这种蒽环类药物在血浆或小鼠评估的六种组织中的药代动力学,推测是因为,在与人暴露相关的剂量下,拉帕替尼对 P 糖蛋白的抑制不会显著改变阿霉素从这些组织隔室中的转运。然而,将拉帕替尼与多西紫杉醇联合使用会显著增加这种化疗药物在肠道中的暴露,这对增强胃肠道毒性具有临床意义。拉帕替尼-多西紫杉醇的显著相互作用可能是 CYP3A4 介导的,这表明在给予这种联合治疗时应谨慎,特别是对于 CYP3A 活性受损的患者,并且应密切监测患者以增强毒性,特别是对肠道的不良影响。

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验